Bloomberg Audio Studios, Podcasts, Radio News.
You're listening to Bloomberg Business Week with Carol Masser and Tim Stenoveek on Bloomberg Radio. Thinking about leverage and trade negotiations between the US and China. We often talk about China's large domestic market and it's rarests, but not that often, Carol, we talk about medicine.
No, we don't, but we are going to talk about it now.
We're going to a Bloomberg piece from last week, actually ahead of this week's meeting between the President and Chinese President. Hijin Pang notes that China's power arrests on its grip over the global supply of active pharmaceutical ingredients or APIs, which are core components of commercial drugs. Beijing's broad sway extends upstream to the raw chemicals, the solvents, the reagents known as key starting materials needed to make the APIs themselves.
Doctor Christina Smolke thinks a lot about this. She's the co founder and CEO of Anthea. It's a pharmaceutical ingredient producer. Their goal is to end at drug shortage. As she joins us from Memlo Park, California, doctor Smolkie. Great to have you on the program. A pharmaceutical ingredient producer. We think about this, I don't. I don't often think about you know, when I take a pill, what actually goes
into the manufacturer of these pills. What I do know is that oftentimes it comes from outside of the United States. Oftentimes the supply chain spans the globe. Is that a national security risk?
Yeah? Thanks for that question. Is it is increasingly being viewed as a national security risk. And the reason is that is based upon the United States reliance on foreign sources for these materials and also the increasing frequency and duration of disruptions we are experiencing in critical life saving medicines.
So tell us a little bit about what you guys are doing specifically. I agree with Tim. I think we just like get our prescriptions, we take them, and not until there's a problem do we like, wait, what's in this stuff? So talk to us about what you are doing or trying to do.
Yes, Anthea has developed a new way to produce these critical life saving pharmaceutical ingredients, and it's leveraging a technology that allows us to do so in a way that is more resilient, more predictable, and addresses a lot of the pain points we see in the current in the
current industry. In particular, what Anthea's technology allows us to do is to shift from producing these medicines overseas in very long as I said, very basically vulnerable multi step processes to a process that looks closer to brewing beer. So we're able to take yeast and we basically modify those yeast so that they can basically, instead of producing beer,
can produce these critical life saving pharmaceutical ingredients. And one of the key advantages of that is then allows us to move those production processes more locally into the United States.
So at what point the processes does that does that happen? I mean, are you are you? Are you taking it from the perspective of okay, you're you understand what goes into a given medication and you can create the ingredients from the yeast then, or or do you sort of reverse engineer it? You take the final product and you say, okay, this is what we need to produce and here's how we can do it. Like, how does that work? Scientifically?
Great? Yes, great question, so scientifically it will it works? As us saying this is the molecule that we want to produce. This is the medicine that we want to produce, So we know the endpoint, we know the structure, and then we basically will modify program the yeast and really teach them through making modifications to their genome to be able to then synthesize those those pharmaceutical ingredients from sugar.
So essentially what the process will look like at the scales, we throw the yeast into a large vat, we feed them sugar, and they're basically working as miniature medicine factories to convert that sugar directly to the pharmaceutical ingredient that then ultimately will be formulated into the medicine that patients take.
So how could this help me understand? How is this being done already?
Yes, it is being done already. So Anthea launched We launched our first product commercially now about a year ago and you know, basically seen tremendous response from the marketing from our customers again really responding to the solutions that this brings in terms of shoring up their supply chains and their ability to have very stable, very consistent supply
of these medicines. So it's now a technology that's fully commercial and you know, one of the I think very powerful things about this technology is it a true platform we've built out While we've launched our first product commercially, we've built out a very large pipeline of pharmaceutical ingredients that we are applying the strategy to and now queued up to basically launch our second and third products.
Shortly, how do you characterize the makeup of the medications or the ingredients that since they're produced from yeast, how are they classified? Like? Are they synthetic? Are they naturally occurring? Like are they basically yes, Yeah, I don't understand that question. Great question.
So one of the things to really highlight here is that we already leverage fermentation to produce medicines in our pharmaceutical supply chain. Insulin is an example of that. You know, we used to extract insulin from animals and now it's all produced via fermentation process. So within the industry, we follow very standard procedures for how the molecules that we produce are characterized. We ensure that they basically are exactly the same as what has already been used in these
meta and meet all of the quality requirements. That are needed to ensure patients not just have access to these life say even to medicines, but that they are safe and consistent for them as well.
Christina, what's the FDA oversight of all of this?
Yes, it's it's These are basically tracked and approved by the FDA. And so again, because the idea of fermenting or using biosynthesis to produce medicines is not novel within the industry, there are regulatory basically steps in terms of how they are approved, and they has already gone through those approval processes. Everything is produced within the quality that the FDA requires.
So what so if a pharmaceutic pharmaceutical company, like, what what is your relationship with a pharmaceutical company? If pharmaceutical company were to come to you and say we want you to manufacture this, is that how it works?
Yeah, at this Dame age, the medicines that we're bringing to market are are again there were focused on the medicines that played the most critical role in public health, but really transforming and rebuilding those supply chains so that drug shortages you know, do not infect patients you know, going forward, and so we're able to basically sell the ingredient.
Two pharmaceutical companies globally, you know, and and there are pharmaceutical customers basically will take that ingredient and then formulate it into the drug product that the patient actually takes.
You know, I ran into an issue a couple of years ago. I've talked about this on air before, but it was with a max of syllin.
Yeah, I remember this.
My Yeah, my son had this terrible ear infection, like just screaming, and the doctor couldn't find a pharmacy that had a max oficillin coming off the pen it was coming off the pandemic. And it was interesting because a few months before that, we had had a I think it was a big take story that talked about the profit margins are so all on some of these generics that it's hard to find producers to actually make these drugs. Ultimately, we did find a pharmacy that had it, thank god.
And you know, you take that medication and within hours that you're infection is better. But is that the type of thing, doctor, that you're trying to solve or is it more advanced drugs more complicated to us than that.
No, it's exactly the type of it's first and foremost is exactly the type of thing that you just highlighted, right, and you're not alone. I've experienced the same thing, whether it's you know, basic antibiotics, cold medicines, you know, things that are required for surgery. It's you know, we don't expect these to be in shortage because they're not the
most advanced kind of latest drugs, but they are. And that's the type of thing that we are that we're bringing to market you know, today right now and solving those issues. And one of the things I would just highlight, you know, coming back to by leveraging this technology, it solves not just being able to synthesize it domestically so that we have greater control and transparency over these supply chain.
It does so at a fraction of the cost, because it's really leveraging a novel technology to make sure that we can synthesize them in more efficient and cost effective ways. So it addresses some of that some of that issue that you just described. I mean, now the same technology can also be applied to new medicines, you know, and advanced medicines as well, and that's really a longer term
trajectory that in THEYA is looking at. But right now, what we're bringing to market are the ones that are most critical for public health.
So when you're doing biologics or biosynthesis, Christina, I mean my understanding. You know, you're using a living organism and engineered systems or living organisms raised a lot of questions when it comes to biosafety or you know, unintended by products, how to regulate them. So I'm just curious. That makes it difficult, right and also providing consistency, so that is one of the things that is is a risk.
It's a great question. And let me highlight a couple things about the technology itself. At the end of the day, the product that we sell and the product that goes to patients, it is a chemical we are not it's you know, the living organism isn't actually not going into the patients. I guess we use a yeast sale to make the product, but ultimately we purify that chemical down to greater than ninety nine you know, percent purity and
meet all of the existing requirements. So it's very well characterized. So that carryover of sort of an uncontrolled you know, living organism into a patient that doesn't happen with this technology. The other thing I will just highlight, and what we have been able to show with this platform is that we can program the synthesis so precisely that we actually are able to provide products that have fewer byproducts than what we see through other manufacturing approaches.
Hey, just lastly, twenty and I know you guys did a Series C about fifty six million dollars. When is it commercially viable? And forgive me, it's just twenty seconds here.
No.
Absolutely, As I mentioned, Anthea is commercial at this stage and we'rek And now what we're doing is we're leveraging that funding, leveraging the support from the investors to really grow and ramp basically how we bring our products to market, what markets we can enter and ensure that this is truly disruptive.
Come back and keep us informed. Christina Smolkey, co founder CEO of Anthea joining us